Valuation: Agenus Inc.

Market Cap 140M 122M 113M 104M 197M 13.35B 201M 1.35B 530M 6.56B 524M 512M 22.64B P/E 2026 *
4.27x
P/E 2027 * -18.6x
Enterprise Value 140M 122M 113M 104M 197M 13.35B 201M 1.35B 530M 6.56B 524M 512M 22.64B EV / Sales 2026 *
0.76x
EV / Sales 2027 * 1.06x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+85.37%
1 week+83.58%
Current month+104.58%
1 month+92.62%
3 months+50.84%
6 months+35.79%
Current year+99.36%
1 week 3.1
Extreme 3.1
8.7
1 month 2.85
Extreme 2.85
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
37.4
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Director

8,547 0.0205%
07-01Free

Director

2,268 0.0054%
06-26Free

Chief Executive Officer

5,364 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+84.93%+83.58%-8.35%-83.08% 140M
+0.44%+1.41%+4.25%+10.81% 50.73B
-2.76%-4.42%+373.29%+584.51% 39.73B
+0.20%+1.07%+30.00%-5.22% 34.69B
+1.70%-1.78%+20.55%+53.38% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-2.74%-1.29% - - 16.8B
-1.56%-6.28%+65.31%+120.28% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-1.10%-3.02%+10.87%-33.42% 12.85B
Average +8.05%-1.28%+57.16%+77.36% 24.4B
Weighted average by Cap. -0.37%-0.38%+80.11%+122.58%

Financials

2026 *2027 *
Net sales 185M 162M 150M 138M 261M 17.68B 266M 1.79B 701M 8.68B 694M 678M 29.98B 131M 115M 107M 98.25M 186M 12.58B 189M 1.27B 499M 6.18B 494M 483M 21.34B
Net income 46M 40.35M 37.37M 34.38M 65.03M 4.4B 66.3M 445M 175M 2.16B 173M 169M 7.47B -9.9M -8.68M -8.04M -7.4M -14M -948M -14.27M -95.85M -37.59M -465M -37.18M -36.36M -1.61B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
13/07/26 $6.233 +86.05% 170,220,077
10/07/26 $3.350 +3.40% 833,400
09/07/26 $3.240 -0.31% 654,170
08/07/26 $3.250 -7.14% 797,540
07/07/26 $3.500 +2.64% 1,164,347
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.350USD
Average target price
19.00USD
Spread / Average Target
+467.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock